FDA Reauthorization Advances to House Floor

Generic Line
A A
The House Energy and Commerce Committee voted unanimously to advance the FDA’s five-year user fee reauthorization package to the floor of the House — following a lengthy debate more on the rising cost of prescription drugs, than on the fee programs at the heart of the bill.

To View This Article:

Login

Subscribe To Generic Line